MarketCap
Facebook
X
Telegram
MTBC Income Statement 2025-2011 | MTBC
Brief overview of revenue and earnings at MTBC
The conclusions below are based on five years of reported results. The revenue attributed to MTBC moved from 105 million dollars to 120 million dollars between the two endpoints. Across the full period, sales moved by +14.6%; the average annual rate was 2.8%. Revenue was effectively stagnant over the period.
The five-year EBITDA result moved by +1547%: from 1.6 million dollars to 26.3 million dollars. EBITDA grew faster than revenue, indicating positive operating leverage. The EBITDA share of revenue changed from 1.5% to 21.8%. Higher profitability strengthens the quality of operating growth.
The net financial result changed from −8.8 million dollars to 10.8 thousand dollars. A negative result turned positive over the five years.
Conclusion
The financial profile remains mixed, with strengths and risks moving in different directions. The positive side is supported by positive operating leverage and improving net profitability. Caution is warranted because of weak sales momentum. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement MTBC
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 55.4 M | 53.7 M | 51.8 M | 91.9 M | 145 M | 58 M | 47.9 M | 40.4 M | 8.13 M | 8.76 M | 17.2 M | - | - | - |
Shares |
37.8 M | 16.1 M | 15.7 M | 15.1 M | 14.5 M | 12.7 M | 12.1 M | 11.7 M | 11 M | 10 M | 9.73 M | 7.08 M | - | - | - |
Historical Prices |
- | 3.43 | 3.43 | 3.43 | 6.32 | 9.07 | 4.06 | 3.8 | 2.61 | 0.725 | 1.2 | 2.34 | - | - | - |
Net Income |
10.8 K | 7.85 K | -48.7 K | 5.43 M | 2.84 M | -8.81 M | -872 K | -2.14 M | -5.57 M | -8.8 M | -4.69 M | -4.51 M | -178 K | 117 K | 470 K |
Revenue |
120 M | 111 M | 117 M | 139 M | 140 M | 105 M | 64.4 M | 50.5 M | 31.8 M | 24.5 M | 23.1 M | 18.3 M | 10.5 M | 10 M | 10.1 M |
Gross Profit |
- | - | - | - | - | 40.3 M | 23.3 M | 19.3 M | 14.1 M | 11.1 M | 11.4 M | 7.67 M | 6.2 M | 5.76 M | 5.58 M |
Operating Income |
11.3 M | 9.12 M | -47.1 M | 6.61 M | 3.53 M | -8.27 M | 67 K | -2.54 M | -4.52 M | -7.9 M | -4.46 M | -4.04 M | -128 K | - | - |
Interest Expense |
-265 K | -298 K | -883 K | -637 K | -96 K | 7 K | -625 K | 494 K | 332 K | -53.3 K | 170 K | -12.6 K | 30.2 K | - | - |
EBITDA |
26.3 M | 23.3 M | -32.7 M | 18.3 M | 15.7 M | 1.6 M | 2.95 M | 387 K | 205 K | -3.51 M | -1.65 M | -3.06 M | 821 K | 701 K | 1.14 M |
Operating Expenses |
109 M | 102 M | 164 M | 132 M | 136 M | 48.6 M | 23.3 M | 21.8 M | 18.2 M | 19.7 M | 17.7 M | 13.5 M | 6.33 M | 5.74 M | 4.99 M |
General and Administrative Expenses |
18.4 M | 16.1 M | 21.5 M | 23.8 M | 24.3 M | 22.8 M | 17.9 M | 16.3 M | 11.7 M | 12.5 M | 12 M | 9.94 M | 4.74 M | 4.4 M | 3.83 M |
All numbers in USD currency
Quarterly Income Statement MTBC
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
42.5 M | 42.4 M | 42.3 M | 23.8 M | 16.3 M | 16.2 M | 16.1 M | 16 M | 15.9 M | 15.8 M | 15.6 M | 15.4 M | 15.2 M | 15.1 M | 15.1 M | 15 M | 14.9 M | 14.7 M | 14.4 M | 14.1 M | 13.4 M | 12.8 M | 12.4 M | 12.3 M | 12.2 M | 12.1 M | 12 M | 11.9 M | 11.8 M | 11.8 M | 11.7 M | 11.6 M | 11.5 M | 11.5 M | 10.8 M | 10.2 M | 10.1 M | 10 M | 10 M | 10.1 M | 10.2 M | 9.73 M | 9.72 M | 9.69 M | 9.71 M | 8.36 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | - | - | - | - | - | - | - | - | - |
Net Income |
922 K | 3.06 M | 2.9 M | 1.95 M | - | 3.12 M | 1.67 M | -241 K | - | -2.75 M | -1.83 M | -401 K | - | 1.06 M | 2.74 M | 1.14 M | - | 1.5 M | -227 K | -1.96 M | - | -1.67 M | -4.79 M | -2.5 M | - | -138 K | -771 K | -296 K | - | -1.83 M | 195 K | 75 K | - | -980 K | -1.69 M | -2.71 M | - | -1.49 M | -1.29 M | -1.98 M | - | -1.23 M | -1.49 M | -1.17 M | - | -2.84 M | -289 K | -384 K | - | -138 K | -178 K | - | - | - | - | - | - | - | - | - |
Revenue |
31.3 M | 31.1 M | 27.4 M | 27.6 M | - | 28.5 M | 28.1 M | 26 M | - | 29.3 M | 29.4 M | 30 M | - | 33.7 M | 37.2 M | 35.3 M | - | 38.3 M | 34.1 M | 29.8 M | - | 31.6 M | 19.6 M | 21.9 M | - | 16.9 M | 16.7 M | 15.1 M | - | 17 M | 8.68 M | 8.31 M | - | 7.51 M | 7.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
1 M | 3.21 M | 3 M | 2.02 M | - | 3.26 M | 2.27 M | 129 K | - | -1.97 M | -1.29 M | -223 K | - | 1.69 M | 2.75 M | 1.22 M | - | 1.42 M | -106 K | -1.68 M | - | -1.24 M | -4.61 M | -2.84 M | - | 669 K | -1.23 M | -238 K | - | -1.78 M | 72.5 K | 39.1 K | - | -275 K | -1.38 M | -2.41 M | - | -1.27 M | -1.07 M | -1.8 M | - | -1.28 M | -1.5 M | -1.17 M | - | -2.4 M | -389 K | -322 K | - | -217 K | -128 K | - | - | - | - | - | - | - | - | - |
Interest Expense |
22 K | -55 K | -35 K | -14 K | - | 60 K | -294 K | 7 K | - | -422 K | -186 K | 17 K | - | -495 K | 112 K | 83 K | - | -65 K | 205 K | -220 K | - | -246 K | -114 K | 445 K | - | -688 K | 545 K | -81 K | - | -219 K | 219 K | 151 K | - | 32.5 K | 36.8 K | 38 K | - | -13.9 K | -24.4 K | -2.07 K | - | 61.9 K | 57.2 K | 14.7 K | - | -36.5 K | -1.56 K | 3.38 K | - | 3.26 K | 2.98 K | - | - | - | - | - | - | - | - | - |
EBITDA |
5.04 M | 7.23 M | 6.38 M | 5.36 M | - | 6.51 M | 5.98 M | 4.06 M | - | 1.93 M | 2.05 M | 2.82 M | - | 4.5 M | 5.69 M | 4.16 M | - | 4.97 M | 3.02 M | 1.15 M | - | 1.97 M | -2.2 M | -1.5 M | - | 1.48 M | -392 K | 519 K | - | -961 K | 632 K | 630 K | - | 389 K | 70.1 K | -890 K | - | -152 K | 135 K | -591 K | - | -140 K | -299 K | -7.62 K | - | -1.15 M | -118 K | -51.9 K | - | 94.6 K | 54.2 K | - | - | - | - | - | - | - | - | - |
Operating Expenses |
30.3 M | 27.9 M | 24.4 M | 25.6 M | - | 25.3 M | 25.8 M | 25.8 M | - | 31.2 M | 30.7 M | 30.2 M | - | 32 M | 34.5 M | 34.1 M | - | 36.9 M | 34.2 M | 31.4 M | - | 32.9 M | 24.2 M | 24.7 M | - | 16.2 M | 18 M | 15.3 M | - | 18.8 M | 8.61 M | 8.27 M | - | 7.79 M | 9.17 M | 10.6 M | - | 6.61 M | 6.28 M | 6.91 M | - | 6.89 M | 7.47 M | 7.3 M | - | 8.42 M | 3 M | 2.9 M | - | 3.16 M | 2.46 M | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
5.5 M | 4.89 M | 4.36 M | 4.33 M | - | 4.38 M | 4.03 M | 3.72 M | - | 5.48 M | 5.92 M | 5.12 M | - | 6.5 M | 6.39 M | 5.58 M | - | 5.92 M | 6.27 M | 5.62 M | - | 6.19 M | 5.39 M | 5.59 M | - | 4.45 M | 5.14 M | 4.16 M | - | 5.13 M | 3.05 M | 2.6 M | - | 2.47 M | 2.77 M | 2.99 M | - | 2.57 M | 2.69 M | 2.91 M | - | 3.09 M | 3.18 M | 3.14 M | - | 3.71 M | 1.45 M | 1.29 M | - | 1.36 M | 1.22 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company MTBC (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B |  USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 6.37 | 0.47 % | $ 118 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
So-Young International
SY
|
$ 1.94 | -1.02 % | $ 151 M |  China |
 |
HealthEquity
HQY
|
$ 104.13 | 2.85 % | $ 8.97 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
American Well Corporation
AMWL
|
$ 10.77 | -3.41 % | $ 173 M | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Zhongchao
ZCMD
|
$ 1.06 | -9.4 % | $ 3.62 M | China |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Progyny
PGNY
|
$ 31.37 | 1.98 % | $ 2.67 B | USA |
 |
Phreesia
PHR
|
$ 11.14 | 2.67 % | $ 665 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.22 | 3.21 % | $ 1.15 B | USA |
 |
Schrödinger
SDGR
|
$ 15.12 | -1.11 % | $ 1.11 B | USA |
 |
Omnicell
OMCL
|
$ 41.4 | -3.83 % | $ 1.9 B | USA |
 |
Health Catalyst
HCAT
|
$ 2.16 | 0.93 % | $ 151 M | USA |
 |
HealthStream
HSTM
|
$ 29.53 | 2.36 % | $ 886 M | USA |
 |
Evolent Health
EVH
|
$ 3.3 | -11.76 % | $ 377 M | USA |
 |
Teladoc Health
TDOC
|
$ 9.18 | -1.92 % | $ 1.62 B | USA |
 |
10x Genomics
TXG
|
$ 46.32 | -1.55 % | $ 5.78 B | USA |
 |
Veeva Systems
VEEV
|
$ 207.91 | 3.33 % | $ 34 B | USA |